Key Performance Indicators
Below are our key performance indicators (KPIs) for each of our four focus areas (Access to Health, Environmental Sustainability, Employees, Ethics & Transparency).
The following list of KPIs serves as baseline measurement for our corporate responsibility activities. These indicators are measured globally unless otherwise noted and cover all of our business units with the exception of joint ventures.
Please click here to download a spreadsheet of all of our performance data, including KPIs.
|Access to Health1|
|Research & Development||2011||2012||2013||2014||2015|
|Top 20 global burdens of illness addressed by our products and pipeline2||53%||55%||88%||88%||88%|
|GCP/PV audits by regulatory agencies or clinical trial investigators that led to significant fines, penalties, warning letters or product seizures||0||0||0||0||0|
|Established significant external licenses and collaborations3||52||61||40||35||64|
|Narrative of compounds provided to product development partnerships4||Online||Online||Online||Online||Online|
|Manufacturing & Supply|
|Annual percentage of units manufactured/sold and recalled during a given year (recall rate globally)5||NR||0.19%||0.11%||0.22%||0.07%|
|Number of local and regional manufacturing partnerships to enable access6||130||84||68||104||179|
|Number of products available by local and regional partnerships6||NA||34||354||499||1,157|
|New product and device registrations7,8,9||179||204||179||176||156|
|Local regulatory agency GCP/PV training requests fulfilled that will help strengthen agency capabilities in agencies’ GCP/PV-compliance-oversight role10||Online||Online||Online||Online||Online|
|Products submitted that have achieved WHO pre-qualification||10||10||11||11||11|
|Number of our products that are supported with differential pricing11,12,13||NA||NA||24||35||35|
|Number of low- and lower-middle-income countries where inter- and/or intra-country pricing has been implemented11,14||NA||NA||70||114||121|
|Investment in patient- and provider-education programs15 (in millions)||$97.8||$71.4||$61.3||$52.3||$80.0|
|Health care workers trained through major programs and partnerships||52,000||38,000||22,000||137,000||18,669|
|Investment in partnerships for activities to address underlying barriers to health, such as health-system strengthening and capacity-building (in millions)||$35||$24||$24||$32||$31|
|People reached through our major programs and partnerships (in millions)||273||269||302||267||188|
|NA: Not available. NR: Not reported.|
1 Unless otherwise noted, data for the Access to Health section are reflective of our Human Health business only; information on our Animal Health business is reported separately.
2 As defined by the Institute for Health Metrics and Evaluation (IHME).
3 Candidates in our company’s research pipeline or under regulatory review are as of February 19, 2016, as reported in the U.S. Securities and Exchange Commission for 10-K., page 16, filed on February 26, 2016. This includes candidates in Phase II or Phase III trials, or under regulatory review as of February 26, 2016. As candidates attain regulatory approval, they are removed from this pipeline view.
4 For information on product-development partnerships, visit the “Partnerships” tab at http://www.msdresponsibility.com/access-to-health/research-development/#tab-5591a965c9e82.
5 Beginning in 2014, this figure includes recalls within our Animal Health business.
6 In 2014, we expanded our reporting to all of our products, including the various strengths and presentations that are sold or distributed through a partnership in local markets, to more accurately reflect our efforts to address local needs.
7 Data include new products and new indications.
8 Data for all years have been updated based on a tracking-system upgrade that corrected miscounts in prior years.
9 For information on new registrations by region, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/#tab-5591b7745c6c4.
10 For information on local regulatory agency GCP/PV training requests, visit http://www.msdresponsibility.com/access-to-health/research-development/clinical-research/.
11 In 2013, we modified our key performance indicators for differential pricing so that we can more broadly capture and accurately reflect our support.
12 Differential pricing intended to facilitate access for the at-need population.
13 Our products include HIV treatments, vaccines and other patented products.
14 Countries as defined by the World Bank 2013 GNI Classification, including UN-defined “least developed countries.”
15 In 2013, we refined our support to prioritize and align resources to complement our core business strategy, which resulted in an overall decrease in funding.
|Greenhouse gas emissions |
(metric tons of CO2e – Scope 1 & 2)
|Water usage (billion gallons)||8.6||8.6||7.5||7.1||6.3|
|Operational waste generated (metric tons)||108,500||109,500||96,300||83,700||70,200|
|1 Includes facilities worldwide.|
2 In accordance with the Greenhouse Gas Protocol, prior-year data have been adjusted to add or remove facilities that have been acquired and sold. Adjustments also reflect changes in methodology to ensure consistency from year to year.
|Diversity & Inclusion||2011||2012||2013||2014||2015|
|Executive roles held by women1,2||35%||31%||31%||31%||34%|
|Women on the Board||17%||17%||17%||17%||21%|
|Underrepresented ethnic groups on the Board||11%||25%||25%||25%||21%|
|Underrepresented ethnic groups of executives (U.S.)2||17%||17%||20%||20%||20%|
|Underrepresented ethnic groups in the workforce (U.S.)||29%||24%||24%||24%||26%|
|Response rate to the Voice Survey3||63%||77%||77%||78%||NA|
|Employees who completed a health assessment (U.S.)||58%||58%||62%||57%||58%|
|Lost-time incident rate (LTIR)||0.30||0.27||0.28||0.20||0.21|
|Recordable injury rate (RIR)||0.74||0.62||0.61||0.57||0.47|
|Employees who took release time according to the global policy on employee volunteerism4||11.0%||15.0%||NA||12.5%||13.8%|
|NA: Not available.|
1 Beginning with 2012, data reported for women are global; previously, these data were limited to the U.S.
2 “Executive” is defined as the chief executive officer and two structural levels below.
3 In 2014, we moved to a biannual administration of our global employee engagement survey.
4 2015 figures are based on employee self-recorded volunteer hours through MSD Gives Back in the U.S. and Puerto Rico, and volunteer hours communicated directly to the Office of Corporate Responsibility for all other countries. 2015 marks the first year in which volunteer-hour reporting is based solely on employee self-report. Prior years included estimates for unrecorded volunteer hours.
|Ethics & Transparency|
|Employees trained on our Code of Conduct||90%||92%||99%||99%||99%|
|Ratio of substantiated allegations to concerns/issues raised||65%||60%||58%||60%||58%|
|Reported concerns regarding privacy practices, breaches of privacy, and losses of personal data and devices that were substantiated1||68%||23%||26%||18%||96%|
|1 Privacy concerns include all concerns escalated to our Privacy Office about the company’s privacy practices. Substantiated concerns are those that are determined to be inconsistent with our privacy standards or that involve the loss of, theft of or unauthorized access to personal data.|